- Home
- MYNZ vs ENSC Comparison
MYNZ vs ENSC Comparison
Compare MYNZ & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- ENSC
- Stock Information
- Founded
- MYNZ 2021
- ENSC 2003
- Country
- MYNZ Germany
- ENSC United States
- Employees
- MYNZ N/A
- ENSC N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- ENSC Health Care
- Exchange
- MYNZ Nasdaq
- ENSC Nasdaq
- Market Cap
- MYNZ 7.9M
- ENSC 6.4M
- IPO Year
- MYNZ 2021
- ENSC N/A
- Fundamental
- Price
- MYNZ $1.28
- ENSC $2.02
- Analyst Decision
- MYNZ Buy
- ENSC
- Analyst Count
- MYNZ 2
- ENSC 0
- Target Price
- MYNZ $14.00
- ENSC N/A
- AVG Volume (30 Days)
- MYNZ 133.9K
- ENSC 81.4K
- Earning Date
- MYNZ 12-29-2025
- ENSC 11-07-2025
- Dividend Yield
- MYNZ N/A
- ENSC N/A
- EPS Growth
- MYNZ N/A
- ENSC N/A
- EPS
- MYNZ N/A
- ENSC N/A
- Revenue
- MYNZ $659,935.00
- ENSC $7,413,722.00
- Revenue This Year
- MYNZ N/A
- ENSC N/A
- Revenue Next Year
- MYNZ $5.03
- ENSC N/A
- P/E Ratio
- MYNZ N/A
- ENSC N/A
- Revenue Growth
- MYNZ N/A
- ENSC 415.58
- 52 Week Low
- MYNZ $1.21
- ENSC $1.62
- 52 Week High
- MYNZ $14.39
- ENSC $12.15
- Technical
- Relative Strength Index (RSI)
- MYNZ 32.80
- ENSC 39.36
- Support Level
- MYNZ $1.43
- ENSC $2.03
- Resistance Level
- MYNZ $1.47
- ENSC $2.14
- Average True Range (ATR)
- MYNZ 0.10
- ENSC 0.11
- MACD
- MYNZ -0.02
- ENSC -0.02
- Stochastic Oscillator
- MYNZ 12.77
- ENSC 26.23
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.